Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Primary Open Angle Glaucoma or Ocular Hypertension Clinical Trial

Official title:
A Double-Masked, Randomized, Placebo-Controlled Study of Trabecular Outflow Facility Following Treatment With Netarsudil Ophthalmic Solution 0.02% (AR-13324) in Subjects With Elevated Intraocular Pressure

Status Completed

Clinical Trial Summary

To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02% compared to placebo

Clinical Trial Description

Trabecular outflow facility is a measure of aqueous humor dynamics; effect of netarsudil on this parameter as well as on intraocular pressure and episcleral venous pressure was evaluated in this study. Netarsudil treatment was given in one eye and placebo given in contralateral eye for 7 consecutive days. ;

Study Design

Related Conditions & MeSH terms

Glaucoma
Glaucoma, Open-Angle
Hypertension
Ocular Hypertension
Primary Open Angle Glaucoma or Ocular Hypertension

Clinical Trial Details

NCT number	NCT03233308
Study type	Interventional
Source	Aerie Pharmaceuticals
Contact
Status	Completed
Phase	Phase 2
Start date	October 20, 2017
Completion date	April 19, 2018

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03310580` - Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension	Phase 2
	Completed	`NCT02822742` - A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study	Phase 3